title: The use of 'Omics technology to rationally improve industrial mammalian cell line performance.
abstract: Biologics represent an increasingly important class of therapeutics, with 7 of the 10 top selling drugs from 2013 being in this class. Furthermore, health authority approval of biologics in the immuno-oncology space is expected to transform treatment of patients with debilitating and deadly diseases. The growing importance of biologics in the healthcare field has also resulted in the recent approvals of several biosimilars. These recent developments, combined with pressure to provide treatments at lower costs to payers, are resulting in increasing need for the industry to quickly and efficiently develop high yielding, robust processes for the manufacture of biologics with the ability to control quality attributes within narrow distributions. Achieving this level of manufacturing efficiency and the ability to design processes capable of regulating growth, death and other cellular pathways through manipulation of media, feeding strategies, and other process parameters will undoubtedly be facilitated through systems biology tools generated in academic and public research communities. Here we discuss the intersection of systems biology, 'Omics technologies, and mammalian bioprocess sciences. Specifically, we address how these methods in conjunction with traditional monitoring techniques represent a unique opportunity to better characterize and understand host cell culture state, shift from an empirical to rational approach to process development and optimization of bioreactor cultivation processes. We summarize the following six key areas: (i) research applied to parental, non-recombinant cell lines; (ii) systems level datasets generated with recombinant cell lines; (iii) datasets linking phenotypic traits to relevant biomarkers; (iv) data depositories and bioinformatics tools; (v) in silico model development, and (vi) examples where these approaches have been used to rationally improve cellular processes. We critically assess relevant and state of the art research being conducted in academic, government and industrial laboratories. Furthermore, we apply our expertise in bioprocess to define a potential model for integration of these systems biology approaches into biologics development.
authors.affiliation: Biologics Development, Global Manufacturing and Supply, Bristol-Myers Squibb Company, 35 South Street, Hopkinton 01748, Massachusetts. amanda.lewis@bms.com.
authors.forename: Amanda M
authors.initials: AM
authors.lastname: Lewis
authors.affiliation: Biologics Development, Global Manufacturing and Supply, Bristol-Myers Squibb Company, 35 South Street, Hopkinton 01748, Massachusetts.
authors.forename: Nicholas R
authors.initials: NR
authors.lastname: Abu-Absi
authors.affiliation: Biologics Development, Global Manufacturing and Supply, Bristol-Myers Squibb Company, 35 South Street, Hopkinton 01748, Massachusetts.
authors.forename: Michael C
authors.initials: MC
authors.lastname: Borys
authors.affiliation: Biologics Development, Global Manufacturing and Supply, Bristol-Myers Squibb Company, 35 South Street, Hopkinton 01748, Massachusetts.
authors.forename: Zheng Jian
authors.initials: ZJ
authors.lastname: Li
mesh_terms: D000818:Animals; D001688:Biological Products / Q000378:metabolism*; D001709:Biotechnology / Q000379:methods*; D018929:Cell Culture Techniques / Q000379:methods*; D002460:Cell Line; D019295:Computational Biology / Q000379:methods; D006801:Humans; D008322:Mammals; D049490:Systems Biology / Q000379:methods
chemical_list: D001688:Biological Products
keywords: CHO; bioprocess; metabolomics; proteomics; rational optimization; transcriptomics